ETR:MOR - MorphoSys Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€91.30 +7.55 (+9.01 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close€91.30
Today's Range€90.80 - €93.10
52-Week Range€49.63 - €88.10
Volume46,730 shs
Average Volume153,687 shs
Market Capitalization$2.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About MorphoSys (ETR:MOR)

MorphoSys logoMorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%

Miscellaneous

EmployeesN/A
Outstanding Shares29,010,000

MorphoSys (ETR:MOR) Frequently Asked Questions

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What price target have analysts set for MOR?

10 brokers have issued 12-month target prices for MorphoSys' shares. Their predictions range from €58.00 to €103.00. On average, they expect MorphoSys' share price to reach €89.10 in the next twelve months. View Analyst Ratings for MorphoSys.

Who are some of MorphoSys' key competitors?

Who are MorphoSys' key executives?

MorphoSys' management team includes the folowing people:
  • Dr. Simon E. Moroney Ph.D., Chairman of Management Board and Chief Exec. Officer
  • Mr. Jens H. Holstein, Chief Financial Officer and Member of Management Board
  • Dr. Malte Peters, Chief Devel. Officer and Member of Management Board (Age 56)
  • Dr. Markus Enzelberger, Chief Scientific Officer
  • Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)

Has MorphoSys been receiving favorable news coverage?

Media headlines about MOR stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MorphoSys earned a news sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 45.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €91.30.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $2.49 billion.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


MarketBeat Community Rating for MorphoSys (MOR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MorphoSys (ETR:MOR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for MorphoSys in the last 12 months. Their average twelve-month price target is €89.10The high price target for MOR is €103.00 and the low price target for MOR is €58.00. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.502.502.442.86
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €89.10€86.50€81.33€85.57

MorphoSys (ETR:MOR) Consensus Price Target History

Price Target History for MorphoSys (ETR:MOR)

MorphoSys (ETR:MOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/24/2018Goldman Sachs GroupSet Price TargetNeutral€86.00View Rating Details
5/23/2018Berenberg BankSet Price TargetBuy€103.00View Rating Details
5/17/2018JPMorgan Chase & Co.Set Price TargetBuy€100.00View Rating Details
5/8/2018Independent ResearchSet Price TargetBuy€103.00View Rating Details
5/4/2018Oddo BhfSet Price TargetBuy€93.00View Rating Details
5/2/2018Royal Bank of CanadaSet Price TargetSell€58.00View Rating Details
5/2/2018CommerzbankSet Price TargetBuy€98.00View Rating Details
5/1/2018Deutsche BankSet Price TargetBuy€95.00View Rating Details
4/9/2018Bryan, Garnier & CoSet Price TargetBuy€91.00View Rating Details
1/19/2018HSBCSet Price TargetSell€64.00View Rating Details
(Data available from 5/26/2016 forward)

Earnings

Dividends

MorphoSys (ETR:MOR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MorphoSys (ETR MOR) Insider Trading and Institutional Ownership History

Insider Trading History for MorphoSys (ETR:MOR)

MorphoSys (ETR MOR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

MorphoSys (ETR MOR) News Headlines

Source:
DateHeadline
MorphoSys (MOR) Given a €86.00 Price Target at Goldman Sachs GroupMorphoSys (MOR) Given a €86.00 Price Target at Goldman Sachs Group
www.americanbankingnews.com - May 24 at 10:33 AM
MorphoSys (MOR) Given a €103.00 Price Target by Berenberg Bank AnalystsMorphoSys (MOR) Given a €103.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - May 23 at 8:22 AM
Can MorphoSys AG (ETR:MOR) Improve Your Portfolio Returns?Can MorphoSys AG (ETR:MOR) Improve Your Portfolio Returns?
finance.yahoo.com - May 21 at 3:53 PM
MorphoSys (MOR) PT Set at €100.00 by JPMorgan ChaseMorphoSys (MOR) PT Set at €100.00 by JPMorgan Chase
www.americanbankingnews.com - May 17 at 2:59 PM
MorphoSys AG: MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 ConferenceMorphoSys AG: MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference
www.finanznachrichten.de - May 17 at 10:34 AM
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 ConferenceMorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference
finance.yahoo.com - May 17 at 10:34 AM
MorphoSys (MOR) PT Set at €103.00 by Berenberg BankMorphoSys (MOR) PT Set at €103.00 by Berenberg Bank
www.americanbankingnews.com - May 15 at 11:51 AM
Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery PlatformsAnalyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms
finance.yahoo.com - May 15 at 10:56 AM
JMP Securities Starts MorphoSys AG (MOR) at Market OutperformJMP Securities Starts MorphoSys AG (MOR) at Market Outperform
www.streetinsider.com - May 14 at 11:16 AM
Want To Invest In MorphoSys AG (ETR:MOR)? Here’s How It Performed LatelyWant To Invest In MorphoSys AG (ETR:MOR)? Here’s How It Performed Lately
finance.yahoo.com - May 14 at 11:16 AM
MorphoSys (MOR) Given Consensus Rating of "Hold" by BrokeragesMorphoSys (MOR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 13 at 10:17 AM
MorphoSys (MOR) Given a €103.00 Price Target by Independent Research AnalystsMorphoSys (MOR) Given a €103.00 Price Target by Independent Research Analysts
www.americanbankingnews.com - May 8 at 3:45 PM
MorphoSys (MOR) Given a €93.00 Price Target by Oddo Bhf AnalystsMorphoSys (MOR) Given a €93.00 Price Target by Oddo Bhf Analysts
www.americanbankingnews.com - May 5 at 1:07 AM
Galapagos NV (GLPG) & MorphoSys Report Initiation of IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis PatientsGalapagos NV (GLPG) & MorphoSys Report Initiation of IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients
www.streetinsider.com - May 4 at 10:03 AM
MorphoSys AGs (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call TranscriptMorphoSys AG's (MPSYF) CEO Simon Moroney on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 10:03 AM
Goldman Sachs Analysts Give MorphoSys (MOR) a €86.00 Price TargetGoldman Sachs Analysts Give MorphoSys (MOR) a €86.00 Price Target
www.americanbankingnews.com - May 3 at 11:42 PM
MorphoSys Posts Wider Loss In Q1; Confirms 2018 Financial Guidance - Quick FactsMorphoSys Posts Wider Loss In Q1; Confirms 2018 Financial Guidance - Quick Facts
www.nasdaq.com - May 3 at 10:03 AM
MorphoSys AG 2018 Q1 - Results - Earnings Call SlidesMorphoSys AG 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 10:03 AM
BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EURBRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR
www.reuters.com - May 3 at 10:03 AM
MorphoSys AG Reports First Quarter 2018 ResultsMorphoSys AG Reports First Quarter 2018 Results
finance.yahoo.com - May 3 at 10:03 AM
MorphoSys AG: MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis PatientsMorphoSys AG: MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients
www.finanznachrichten.de - May 2 at 10:05 AM
MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis PatientsMorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients
finance.yahoo.com - May 2 at 10:05 AM
MorphoSys (MOR) Given a €58.00 Price Target at Royal Bank of CanadaMorphoSys (MOR) Given a €58.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - May 2 at 8:22 AM
MorphoSys (MOR) Given a €98.00 Price Target by Commerzbank AnalystsMorphoSys (MOR) Given a €98.00 Price Target by Commerzbank Analysts
www.americanbankingnews.com - May 2 at 7:32 AM
MorphoSys (MOR) PT Set at €95.00 by Deutsche BankMorphoSys (MOR) PT Set at €95.00 by Deutsche Bank
www.americanbankingnews.com - May 1 at 9:41 AM
Advisory Live: What is the outlook for healthcare IPOs?Advisory Live: What is the outlook for healthcare IPOs?
www.nasdaq.com - April 30 at 10:29 AM
MorphoSys AG: MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South KoreaMorphoSys AG: MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea
www.finanznachrichten.de - April 27 at 3:51 PM
BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South KoreaBRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea
www.reuters.com - April 27 at 10:50 AM
Why MorphoSys AG (ETR:MOR) Could Be A BuyWhy MorphoSys AG (ETR:MOR) Could Be A Buy
finance.yahoo.com - April 27 at 10:50 AM
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South KoreaMorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea
finance.yahoo.com - April 27 at 10:50 AM
MorphoSys AG: Updated Corporate Calendar 2018MorphoSys AG: Updated Corporate Calendar 2018
www.baystreet.ca - April 25 at 10:31 AM
MorphoSys to Host Q1 2018 Conference Call on May 3, 2018MorphoSys to Host Q1 2018 Conference Call on May 3, 2018
finance.yahoo.com - April 25 at 10:31 AM
BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 MillionBRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
www.reuters.com - April 24 at 10:08 AM
IPO News This Week: DocuSign Tops List of 6 Scheduled OfferingsIPO News This Week: DocuSign Tops List of 6 Scheduled Offerings
www.msn.com - April 22 at 4:20 PM
MorphoSys AG (MOR) IPO Opens Modestly HigherMorphoSys AG (MOR) IPO Opens Modestly Higher
www.streetinsider.com - April 20 at 10:31 AM
Cancer biotech MorphoSys prices $208 million US offering at $25.04Cancer biotech MorphoSys prices $208 million US offering at $25.04
www.nasdaq.com - April 19 at 10:15 AM
BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On NasdaqBRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
www.reuters.com - April 19 at 10:15 AM
BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADSBRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS
www.reuters.com - April 18 at 10:22 AM
MorphoSys (MOR) Given Average Rating of "Hold" by BrokeragesMorphoSys (MOR) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 9:40 AM
Goldman Sachs Reiterates €55.00 Price Target for MorphoSys (MOR)Goldman Sachs Reiterates €55.00 Price Target for MorphoSys (MOR)
www.americanbankingnews.com - April 18 at 12:34 AM
MorphoSys (MOR) PT Set at €55.00 by Goldman SachsMorphoSys (MOR) PT Set at €55.00 by Goldman Sachs
www.americanbankingnews.com - April 16 at 10:54 PM
Commerzbank Reiterates "€76.00" Price Target for MorphoSys (MOR)Commerzbank Reiterates "€76.00" Price Target for MorphoSys (MOR)
www.americanbankingnews.com - April 16 at 10:54 PM
MorphoSys (MOR) PT Set at €90.00 by Deutsche BankMorphoSys (MOR) PT Set at €90.00 by Deutsche Bank
www.americanbankingnews.com - April 14 at 3:38 PM
MorphoSys (MOR) Given a €68.00 Price Target by Berenberg Bank AnalystsMorphoSys (MOR) Given a €68.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - April 13 at 9:58 PM
MorphoSys Finalizes U.S. IPO TermsMorphoSys Finalizes U.S. IPO Terms
seekingalpha.com - April 13 at 3:51 PM
Deutsche Bank Analysts Give MorphoSys (MOR) a €90.00 Price TargetDeutsche Bank Analysts Give MorphoSys (MOR) a €90.00 Price Target
www.americanbankingnews.com - April 13 at 9:59 AM
MorphoSys AG: MorphoSys Nominates New Candidates for Supervisory BoardMorphoSys AG: MorphoSys Nominates New Candidates for Supervisory Board
www.finanznachrichten.de - April 10 at 3:50 PM
MorphoSys Nominates New Candidates for Supervisory BoardMorphoSys Nominates New Candidates for Supervisory Board
finance.yahoo.com - April 10 at 10:39 AM
BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC FilingBRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
www.reuters.com - April 9 at 10:30 AM
Bryan, Garnier & Co Analysts Give MorphoSys (MOR) a €91.00 Price TargetBryan, Garnier & Co Analysts Give MorphoSys (MOR) a €91.00 Price Target
www.americanbankingnews.com - April 9 at 7:31 AM

SEC Filings

MorphoSys (ETR:MOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

MorphoSys (ETR MOR) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.